RVL Pharmaceuticals Earnings, Revenue miss In Q3

  • Investing.com
RVL Pharmaceuticals Earnings, Revenue miss In Q3

Investing.com - RVL Pharmaceuticals reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.

RVL Pharmaceuticals announced earnings per share of $-0.160 on revenue of $10.02M. Analysts polled by Investing.com anticipated EPS of $-0.160 on revenue of $10.03M.

RVL Pharmaceuticals shares are down 53.92% from the beginning of the year and are trading at $1.440 , down-from-52-week-high.

RVL Pharmaceuticals follows other major Healthcare sector earnings this month

RVL Pharmaceuticals's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.

J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100